InMed Pharmaceuticals, Inc. (IMLFF: OTCQB) | InMed Pharmaceuticals Announces Appointment of Veteran Biotech CFO, Jeff Charpentier


VANCOUVER, Dec. 15, 2016 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Jeff Charpentier, CPA, CA as InMed’s Chief Financial Officer Corporate Secretary.  

Mr. Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of $150M and concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.

“We are extremely pleased to welcome Jeff to the InMed executive team,” notes Eric A. Adams, President CEO. “This is an exciting stage in InMed’s development and Jeff’s extensive track-record in helping health care organizations plan and execute growth strategies makes him an ideal fit for our organization.  As we enter 2017, the complexity and diversity of our drug development plans will increase and having a seasoned biotech financial executive onboard is vital.”

On behalf of the Board of InMed, the Company would like to extend its warmest gratitude to the outgoing CFO, Terese Gieselman for her numerous valuable contributions to InMed since its inception and wishes her the best in her future endeavors.

About InMed

InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.

For more information, visit

Cautionary Note Regarding Forward-Looking Information

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations.  These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct.  We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.


SOURCE InMed Pharmaceuticals Inc.

Leave a Reply